Upleganan
Small moleculeexperimental
Clinical trial activity
3 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Dec 18, 2018 (NCT03792308)
Timeline
2010s
- Jan 1, 2018
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Lipopolysaccharide (LPS)INHIBITOR
Lipopolysaccharide (LPS) inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CC(C)C[C@@H]1NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CN)NC(=O)[C@@H](NC(=O)C[C@H](CN)c2cccc(Cl)c2)[C@@H](C)O)CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC1=O- Mol. weight
- 1144.77 g/mol
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5314491 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04865393 | Phase 1 | Jun 8, 2021 | Department of Defense, Spero Therapeutics |
| NCT04868292 | Phase 1 | Jun 3, 2021 | Department of Defense, Spero Therapeutics |
| NCT03792308 | Phase 1 | Dec 18, 2018 | Clinical Network Services, Scientia Clinical Research Limited Sydney, Spero Therapeutics |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Spero Therapeutics | For profit | 3 | 3 | 1 | 2018 |
| Department of Defense | Government | 2 | 0 | 1 | 2021 |
| Clinical Network Services | For profit | 1 | 0 | 1 | 2018 |
| Scientia Clinical Research Limited Sydney | For profit | 1 | 0 | 1 | 2018 |
4 organizations
Page 1 / 1